首页 | 本学科首页   官方微博 | 高级检索  
   检索      


A genetically engineered strain of Saccharopolyspora erythraea that produces 6,12-dideoxyerythromycin A as the major fermentation product
Authors:D Stassi  D Post  M Satter  M Jackson  G Maine
Institution:(1) Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, Abbott Laboratories, D-4FR F3-3, 1401 Sheridan Road, North Chicago, IL 60064, USA Tel.: +1 847 938 7389 Fax: +1 847 935 2701 e-mail: diane.stassi@abbott.com, US;(2) Chemical and Agricultural Products Division, Abbott Laboratories, North Chicago, IL 60064, USA, US
Abstract:The erythromycin producer, Saccharopolyspora erythraea ER720, was genetically engineered to produce 6,12-dideoxyerythromycin A, a novel erythromycin derivative, as the major macrolide in the fermentation broth. Inspection of the biosynthetic pathway for erythromycin would suggest that production of this compound could be achieved simply through the disruption of two genes, that encoding the erythromycin C-6 hydroxylase (eryF ) and that encoding the erythromycin C-12 hydroxylase (eryK ). The double mutant, however, was found to produce a mixture of 6,12-dideoxyerythromycin A and the precursor, 6-deoxyerythromycin D. Complete conversion to the desired product (to the limit of detection by TLC) was achieved by inserting an additional copy of the eryG gene, encoding the erythromycin 3′′-O-methyltransferase and driven by the ermE* promoter, into the S. erythraea chromosome. Received: 6 October 1997 / Received revision: 27 January 1998 / Accepted: 24 February 1998
Keywords:
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号